Cambridge Cognition Investment, Monument Therapeutics, Announces First Patient Dosed in Clinical Trial of MT1988 in Patients at Clinical High Risk for Psychosis

Cambridge UK, March 10, 2026 - Cambridge Cognition (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, reports that Monument Therapeutics Limited (“Monument”), in which the Group has a 20% shareholding, has announced the dosing of the first patient in its clinical trial with MT1988, to treat patients at clinical high risk (CHR) for psychosis.

The study is being conducted in collaboration with the Foundation for the National Institutes of Health (FNIH) as part of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) program. This trial marks a major step forward in developing treatment options for people at risk of schizophrenia.

The randomised, placebo-controlled, proof-of-principle study will enrol 150 CHR participants who will receive one of two dose levels of MT1988 or placebo over an eight-week treatment period. The trial will evaluate the potential of MT1988 to improve cognitive symptoms in CHR individuals, incorporating a range of clinical and cognitive biomarkers. This approach is designed to assess not only therapeutic effects but also the potential of these biomarkers to predict and monitor treatment response.

Cambridge Cognition's proprietary digital cognitive assessment technologies supported the early development of MT1988 and were instrumental in establishing the foundational biomarker strategy for Monument.

Sheryl Caswell, Chief Development Officer of Monument Therapeutics said “Dosing our first patient marks a pivotal moment for Monument Therapeutics and for people at risk of developing psychosis, because, despite the significant impact of this early stage of illness, there are currently no approved pharmacological treatments for the CHR population.”

Rob Baker, Chief Executive Officer - Cambridge Cognition said, “We congratulate our colleagues at Monument for achieving this milestone in MT1988’s development. Treatment of the first patient represents a significant value inflection point for Monument. We believe using both biological biomarkers and Cambridge Cognition’s digital assessments of cognitive function to assess MT1988 will provide insights into the underlying biology and also capture observable changes in cognitive function.”